Trustees

Michael W. Bonney

Trustee, HQH, HQL (since 2011), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Director, Cubist Pharmaceuticals, Inc. (2012-2014); President, Chief Executive Officer and Director, Cubist Pharmaceuticals, Inc. (2003-2012); Director, NPS Pharmaceuticals, Inc. (2012-2015); Chairman of the Board of Trustees, Bates College (since 2010); Chairman of the Board of Trustees, Alnylam Pharmaceuticals (since 2015); Board member, CELGENE Corporation (since 2015); Board member, Global Blood Therapeutics (since 2016); Board member, Revolution Medicine (since 2016); Board member, Gulf of Maine Research Institute (since 2016); Board member, Whitehead Institute for Biomedical Research (since 2015); and Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) (2009-2014).

Rakesh K. Jain, Ph.D.

Trustee, HQH, HQL (since 2007), THQ (since 2014) and THW (since 2015); Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (since 2011).

Daniel R. Omstead, Ph.D. *

Trustee, HQH, HQL (since 2003), THQ (since 2014) and THW (since 2015); President, HQH, HQL (since 2001), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002); Director: GenomDx Biosciences Inc. (since 2016); IlluminOss Medical, Inc. (since 2012); Dynex Corporation (since 2012); Neurovance, Inc. (since 2015); EBI Life Sciences, Inc. (since 2015); Euthymics Biosciences, Inc. (since 2015); Veniti, Inc. (since 2015).

Oleg M. Pohotsky, MBA, J.D. 

Trustee, HQH, HQL (since 2000) THQ (since 2014) and THW (since 2015); Consultant and Managing Partner, Right Bank Partners (since 2002); Adviser, Board Advisers, Kaufman & Co. LLC (since 2008); Director, Avangard Investment Holdings (since 2010); Director, The New America High Income Fund, Inc. (since 2013).

William S. Reardon, MBA

Trustee, HQH, HQL (since 2010), THQ (since 2014) and THW (since 2015); Independent Consultant (since 2002); Director, Idera Pharmaceuticals, Inc (since 2002).

Uwe E. Reinhardt, Ph.D. 

Trustee, HQH (since 1988), HQL (since 1992), THQ (since 2014) and THW (since 2015); Professor of Economics, Princeton University (since 1968); Director, Boston Scientific Corporation (since 2002); Director, Amerigroup, Inc. (since 2002).

Lucinda H. Stebbins, CPA 

Trustee, HQH, HQL (since 2006), THQ (since 2014) and THW (since 2015); Independent Consultant, Deutsche 4 Bank (2004-2015); Director, Bald Peak Land Company, Inc. (2008-2014), Director, Solstice Home Care, Inc. (since 2014).

* Trustee considered to be an “interested person” within the meaning of the Investment Company Act of 1940, as amended, through a position or affiliation with Tekla Capital Management LLC.